The purpose of this study is to assess the safety, tolerability, efficacy, and pharmacokinetics (PK) of subcutaneous (SC) MBL949 in obese participants with or without T2DM on weight loss.~Eligible participants will be evaluated for status of glucose homeostasis for stratified enrolment based on whether they are normoglycemic, have impaired glucose tolerance or T2DM.~Participants will be randomized to one of five MBL949 arms or placebo, administered by subcutaneous (SC) injection during the treatment period:~MBL949 Arm 1: One dose C followed by two doses E followed by five doses D of MBL949 Arm 2: Two doses C followed by six doses D of MBL949 Arm 3: One dose G followed by seven doses D of MBL949 Arm 4: One dose A followed by seven doses B of MBL949 Arm 5: One dose C followed by two doses E followed by five doses F of MBL949.~Participants will be evaluated for safety, tolerability, efficacy, and PK during the treatment and follow-up period
The purpose of this study is to assess the safety, tolerability, efficacy, and pharmacokinetics (PK) of subcutaneous (SC) MBL949 in obese participants with or without type 2 diabetes mellitus (T2DM) on weight loss.